跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-11
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-12

10月12日週一 · 今天

10月13日週二

過往

已發布 · 最新在前

8月28日週五

產品

07:00
GlobeNewswire

Roche's Vabysmo shows sustained two-year results in difficult-to-treat nAMD

Roche reported that Vabysmo demonstrated sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration. This is follow-up data on an already-approved product, so it is graded as incremental.

大盤 開啟原文 ↗

8月27日週四

財報

15:43
Yahoo Finance

Canadian Solar Q2 Loss Wider Than Estimates, Revenues Fall Y/Y

Canadian Solar reported a Q2 2026 loss of $1.40 per share versus a consensus estimate of a $1.01 loss and a year-ago loss of $0.08. Revenue of $1.21 billion topped the $1.17 billion consensus but fell 28.7% from $1.69 billion a year earlier, and solar modules recognized as revenue totaled 3.1 gigawatts, down 25% year over year. The company guided Q3 revenue to $1.30-$1.50 billion with gross margin of 13.5%-15.5%, below the $1.65 billion Q3 consensus cited in the article.

大盤 開啟原文 ↗

產品

15:00
Yahoo Finance

RTX's Raytheon completes $50 million expansion of Mississippi manufacturing facility

RTX's Raytheon business completed a $50 million, 17,000 square-foot expansion of its Forest, Mississippi plant, bringing the site to 445,000 square feet of manufacturing space. The facility builds electronic warfare and radar systems including Next Generation Jammer Mid-Band pods for the U.S. Navy and the Australian government, and the expansion is expected to add 100 high-skill positions by 2028.

大盤 開啟原文 ↗

合作

12:50
GlobeNewswire

argenx completes acquisition of Forte Biosciences

argenx announced it has completed its acquisition of Forte Biosciences, Inc. Forte is not in this universe, so it is not listed as a counterparty. Consideration is not stated in the headline and is not reproduced here.

大盤 開啟原文 ↗

產品

11:30
Clinical Trials Arena

Amgen-AstraZeneca's Tezspire nets another Phase III inflammatory disease win

Tezspire, co-developed by AstraZeneca and Amgen, hit its endpoints in a Phase 3 trial in eosinophilic esophagitis, opening a potential new indication.

大盤 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天